Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
I just attended my first CROI (Conference on Retroviruses and Opportunistic Infections). It was also my first virtual conference...
The week of March 6 – March 10, 2021 I had the privilege of attending the Conference on Retroviruses and Opportunistic Infections (CROI).
Long-acting antiretrovirals were the big news at CROI this year; now two of the most promising are joining forces.
A study finds that long-acting cabotegravir is an effective PrEP option for women.
Cabotegravir injections and daily Truvada are both highly effective, but some people may find it easier to use the long-acting regimen.
Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.
A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.
COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.
The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.
A new long-acting injectables HIV drug shows promise in monkey study.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.